Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post on LinkedIn:
“PARP inhibitors: are we finally doing precision medicine… or just empirical combinations?
For PARPi lovers in gyn onc – two new Annals of Oncology editorials, with interesting lessons.
Metastatic uLMS progressing on anthracycline-based CHT (TOMAS2 trial – uLMS subgroup): a glimpse of true precision?
– 12-month PFS: 42.9% trabectedin-olaparib vs 0% trabectedin.
– PARP1+ tumors: median PFS 13.7 vs 2.4 months.
Not practice-changing – but biologically compelling.
– PARPi seem to work when the tumor is “wired” for it – biomarker refinement is essential (PARP1, BRCA, HRD).
Ovarian cancer: the PARPi + IO paradox
Four big trials (ATHENA-COMBO, DUO-O, KEYLINK-001, FIRST), positive PFS… but:
– unclear added value of immunotherapy,
– no convincing signal of synergy
Jonathan Ledermann – Robert L. Coleman Thanks for this outstanding Editorial!
Take-home for PARPi enthusiasts:
PARPi are here to stay, but the future is not more combinations – it’s better selection, more biology-driven precision. We need to move from ‘PARPi for many’ to PARPi for the right patients.”
Other articles featuring Giuseppe Caruso on OncoDaily.